Drug Trial Radar · NCT05409911
A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
Last checked: Nov 20, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Sep 13, 2022
Primary completion
Apr 25, 2023
Study completion Apr 25, 2023
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Jun 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of S-217622 in participants with mild and moderate hepatic impairment compared with control participants with normal hepatic function.
Conditions
- Hepatic Impairment
Interventions
S-217622Drug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Time to Maximum Plasma Concentration (Tmax) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Area Under the Plasma Concentration-Time Curve (AUC) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Terminal Elimination Half-Life (t1/2,z) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Terminal Elimination Rate Constant (λz) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Mean Residence Time (MRT) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Apparent Total Clearance (CL/F) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Apparent Volume of Distribution (Vz/F) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Renal Clearance (CLR) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Fraction of Dose Excreted in Urine (Feu) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
- Fraction Unbound in Plasma (FU) of S-217622Time frame: 0 (predose) up to 336 hours postdose on Day 1 to Day 15
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami, LLC
Miami, Florida
Advanced Pharma CR, LLC
Miami, Florida
Orlando Clinical Research Center, Inc.
Orlando, Florida
Nucleus Network
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.